Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Lunch and Poster Display session

257P - A low fT3/fT4 ratio as a negative prognostic factor in patients with metastatic breast cancer

Date

16 May 2024

Session

Lunch and Poster Display session

Presenters

Paola Zagami

Citation

Annals of Oncology (2024) 9 (suppl_4): 1-47. 10.1016/esmoop/esmoop103200

Authors

R. Scafetta1, F. Loupakis2, R.M. Marsicano3, A. Carnevale Schianca3, A. Esposito4, B. Taurelli Salimbeni3, P. Zagami3, A. Marra5, D. Trapani4, G. Curigliano3, C. Criscitiello3

Author affiliations

  • 1 Policlinico Universitario Campus Bio-Medico, Rome/IT
  • 2 3trees Healthcare, Viterbo/IT
  • 3 IEO - Istituto Europeo di Oncologia IRCCS, Milan/IT
  • 4 European Institute of Oncology IRCCS, 20141 - Milan/IT
  • 5 European Institute of Oncology IRCCS, Milan/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 257P

Background

Low levels of free triiodothyronine (fT3) predict worse outcomes across various medical conditions even in the absence of the so called non thyroidal illness syndrome. fT3/fT4 ratio better reflects peripheral deiodination activity and holds promise for stratifying patients (pts) with normal fT3 levels. A reduced fT3/fT4 ratio has been linked to worse outcomes in pts with various metastatic cancers. In this study, we aimed to explore the potential prognostic effect of fT3/fT4 in pts with metastatic breast cancer (mBC).

Methods

We conducted a retrospective analysis of pts with mBC enrolled in phase I/II trials at the European Institute of Oncology. Clinical data and baseline blood test results were collected at the initiation of the experimental treatment. PFS and OS were analysed by means of Kaplan Meier. Study population was categorised in High vs Low levels of fT3/fT4 ratio groups using the median as the cutoff point.

Results

36 pts with available fT3/fT4 ratio results were included. Median age at diagnosis was 43 years (IQR 26-67), median number of previous treatment lines was 2 (IQR 0-9). At diagnosis, 69% of pts had visceral metastases, 36% had hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) BC, while 22% and 36% had HER2+ and triple-negative BCs, respectively. The median value of fT3/fT4 was 0.267. Among pts with low fT3/fT4 ratio 88% had visceral metastasis compared to 52% in the group with high fT3/fT4 ratio (p=0.021). Neither age nor the number of previous lines of treatment or albumin levels were different across the fT3/fT4 ratio groups. Pts with a low fT3/fT4 ratio had a mPFS of 1.6 months and a mOS of 6.0 months compared to 1.8 and 20.0 months, respectively, for pts with a high fT3/fT4 ratio (PFS HR=0.81, 95%CI 0.41-1.58, p=NS; OS HR=0.43, 95%CI 0.20-0.94, p=.008). At MV analyses including the presence of visceral metastasis as covariate only fT3/fT4 ratio retained its significant association with OS (p=0.004).

Conclusions

Our data suggest that fT3/fT4 ratio, may deserve further investigation as a negative prognostic marker in patients with mBC. Given the small sample size, these exploratory survival analyses as well as the associations with other well known prognostic features should be interpreted with caution.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

A. Esposito: Financial Interests, Personal, Invited Speaker: Novartis, AstraZeneca. A. Marra: Financial Interests, Personal, Advisory Board: Menarini/Stemline; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Other, Travel Support: AstraZeneca. G. Curigliano: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, Daiichi Sankyo, Novartis, Pfizer, Pfizer; Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Daiichi Sankyo, Lilly, Pfizer, Veracyte, BMS, Merck, Exact Sciences, Celcuity; Financial Interests, Personal, Advisory Board, Advisory Board: Menarini, Gilead; Financial Interests, Personal, Other, Advisory Board: Ellipsis; Financial Interests, Institutional, Research Grant, Investigator Initiated Trial: Merck; Financial Interests, Institutional, Funding, Phase I studies: BMS, Novartis, AstraZeneca, Daiichi Sankyo, Roche, Blueprint Medicine, Kymab, Astellas, Sanofi, Philogen; Financial Interests, Institutional, Invited Speaker, Phase I clinical basket trial: Relay Therapeutics; Non-Financial Interests, Officer, Italian National Health Council as Advisor for Ministry of Health: Consiglio Superiore di Sanità; Non-Financial Interests, Advisory Role, Member of the Scientific Council. Patient advocacy association: Europa Donna; Non-Financial Interests, Advisory Role, Cancer Research Foundation: Fondazione Beretta; Non-Financial Interests, Member of Board of Directors, No compensation for this role. This a public national company for cancer prevention: Lega Italiana Lotta ai Tumori; Non-Financial Interests, Officer, Member of the Advisory Council: EUSOMA; Non-Financial Interests, Officer, ESMO Clinical Practice Guidelines Chair: ESMO; Non-Financial Interests, Member of Board of Directors, Chair of Clinical Practice Guidelines Committee: ESMO. C. Criscitiello: Financial Interests, Personal, Invited Speaker: Pfizer, Novartis, Eli Lilly, Roche, Gilead; Financial Interests, Personal, Advisory Board: MSD, Seagen, AstraZeneca, Daiichi Sankyo. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.